Frieder Haenisch1, Murtada Alsaif1, Paul C Guest1, Hassan Rahmoune1, Faith Dickerson2, Robert Yolken3, Sabine Bahn4. 1. Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK. 2. Sheppard Pratt Health System, Baltimore, MD, USA. 3. Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK; Department of Neuroscience, Erasmus Medical Centre, Rotterdam, The Netherlands. Electronic address: sb209@cam.ac.uk.
Abstract
BACKGROUND: Our understanding of bipolar disorder (BD) aetiology has advanced in recent years but our ability to translate this to improve patient care in the clinic is still limited. METHODS: In this study, we have measured the concentrations of 190 different molecules using sensitive multiplex immunoassays in plasma of 17 BD patients compared to 46 matched control subjects. RESULTS: The analyses led to the identification of 26 dysregulated proteins in BD patients compared to controls. These molecules were comprised mostly of growth factors, hormones, lipid transport and inflammatory proteins. Decreased apolipoprotein A1 has previously been associated with BD patients and this was confirmed in our study. LIMITATIONS: The present pilot study was limited by its small sample size, use of multiple drug treatments and the lack of dietary restrictions at the time of sampling. CONCLUSIONS: Future studies may increase our understanding of BD which will help to pave the way for much-needed patient stratification for better treatment outcomes.
BACKGROUND: Our understanding of bipolar disorder (BD) aetiology has advanced in recent years but our ability to translate this to improve patient care in the clinic is still limited. METHODS: In this study, we have measured the concentrations of 190 different molecules using sensitive multiplex immunoassays in plasma of 17 BDpatients compared to 46 matched control subjects. RESULTS: The analyses led to the identification of 26 dysregulated proteins in BDpatients compared to controls. These molecules were comprised mostly of growth factors, hormones, lipid transport and inflammatory proteins. Decreased apolipoprotein A1 has previously been associated with BDpatients and this was confirmed in our study. LIMITATIONS: The present pilot study was limited by its small sample size, use of multiple drug treatments and the lack of dietary restrictions at the time of sampling. CONCLUSIONS: Future studies may increase our understanding of BD which will help to pave the way for much-needed patient stratification for better treatment outcomes.
Authors: Y R Song; B Wu; Y T Yang; J Chen; L J Zhang; Z W Zhang; H Y Shi; C L Huang; J X Pan; P Xie Journal: Braz J Med Biol Res Date: 2015-09-08 Impact factor: 2.590
Authors: M Bot; M K Chan; R Jansen; F Lamers; N Vogelzangs; J Steiner; F M Leweke; M Rothermundt; J Cooper; S Bahn; B W J H Penninx Journal: Transl Psychiatry Date: 2015-07-14 Impact factor: 6.222
Authors: Carmen Rodríguez Cerdeira; Elena Sánchez-Blanco; Beatriz Sánchez-Blanco; Jose Luis González-Cespón Journal: Int J Immunopathol Pharmacol Date: 2017-01-24 Impact factor: 3.219
Authors: Ashley L Comes; Sergi Papiol; Thorsten Mueller; Philipp E Geyer; Matthias Mann; Thomas G Schulze Journal: Transl Psychiatry Date: 2018-08-16 Impact factor: 6.222
Authors: M A Frye; M Nassan; G D Jenkins; S Kung; M Veldic; B A Palmer; S E Feeder; S J Tye; D S Choi; J M Biernacka Journal: Transl Psychiatry Date: 2015-12-08 Impact factor: 6.222
Authors: Man K Chan; Jason D Cooper; Stefanie Heilmann-Heimbach; Josef Frank; Stephanie H Witt; Markus M Nöthen; Johann Steiner; Marcella Rietschel; Sabine Bahn Journal: Sci Rep Date: 2017-10-03 Impact factor: 4.379